Aptose Tuspetinib Clinical Data Selected For Oral Presentation At The 2023 ASH Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Aptose Biosciences Inc. (NASDAQ:APTO) announced that clinical data for its drug tuspetinib has been selected for oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting in December 2023. The data will be presented by Naval Daver from the University of Texas MD Anderson Cancer Center and will include updates from Aptose's ongoing APTIVATE trial of tuspetinib in patients with acute myeloid leukemia.
November 02, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aptose Biosciences' tuspetinib clinical data being selected for presentation at a major conference could potentially boost investor confidence in the company and its product.
The selection of Aptose's clinical data for presentation at a major conference indicates recognition from the scientific community, which could positively impact the company's reputation and investor confidence. However, the actual impact will depend on the data presented and the reaction of the medical community.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100